Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: Data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/μL)

HIV Medicine

Volumn 5, Issue 1, 2004, Pages 1-10

  Floridia, Marco ^a   Bucciardini, R ^a   Fragola, V ^a   Galluzzo, C M ^a   Giannini, G ^a   Pirillo, M F ^a   Amici, R ^a   Andreotti, M ^a   Ricciardulli, D ^b   Tomino, C ^c   Vella, S ^a   Abrescia, N ^d   Boccia, L ^d   Butrico, E ^d   Vegezio, A ^d   Busto, A ^d   Aceti, A ^d   Mura, M S ^d   Calia, G N ^d   Lovigu, C ^d   Babudieri, S ^d   Oggiano, S ^d   Masia, R ^d   Aiuti, F ^d   Mezzaroma, I ^d   D'Offizi, G ^d   Carlesimo, M ^d   Giovannetti, A ^d   Pinter, E ^d   Alberici, F ^d   Sisti, M ^d   Sacchini, D ^d   Faggi, A ^d   Paolillo, F ^d   Angioni, G ^d   Meloni, G ^d   Angioni, S ^d   Albeltino, G ^d   Porcu, F ^d   Bassetti, D ^d   Gatti, G ^d   Di Biagio, A ^d   Mazzarello, G ^d   Bonazzi, L ^d   Barchi, E ^d   Testa, L ^d   Ursitti, M A ^d   Zoboli, G ^d   Cadeo, G P ^d   Barni, C ^d   Bertelli, D ^d   Cadrobbi, P ^d   Cattelan, A ^d   Meneghetti, F ^d   Sattin, A ^d   Scaggiante, R ^d   Giacomazzi, D ^d   Caggese, L ^d   Moioli, M C ^d   Volonterio, A ^d   Schlacht, I ^d   Errante, I ^d   Irato, L ^d   Caputo, R ^d   Cusini, M ^d   Cagnel, A ^d   Valsecchi, L ^d   Beretta, R ^d   Carosi, G ^d   Chiodera, A ^d   Castelli, F ^d   Tomasoni, L ^d   Cattane, A A ^d   Nasta, P ^d   Chiodo, F ^d   Colangeli, V ^d   Manfredi, R ^d   Borderi, M ^d   Donzelli, C ^d   Guerra, E ^d   Chirianni, A ^d   Gargiulo, M ^d   Montesarchio, V ^d   Punzi, R ^d   Sangiovanni, V ^d   Gnarini, R ^d   Ciammarughi, R ^d   Arlotti, M ^d   Martelli, M L ^d   Romagnoli, G ^d   Boschi, A ^d   Colomba, A ^d   Prestileo, T ^d   Fundaro S ^d   Di Lorenzo, F ^d   Mineo, M ^d   Dalle Nogare, E R ^d   Concia, E ^d   Di Perri, G ^d   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ASL RM/E   (Italy)

^c MINISTRY OF HEALTH   (Italy)

^d NONE

Author keywords

HIV; Protease inhibitors; Rash

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; EFAVIRENZ; GLUCOCORTICOID; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PREDNISONE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ERUPTIONS; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; RISK FACTORS; RITONAVIR; SEX FACTORS; VIRAL LOAD;

EID: 10744220505     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00177.x     Document Type: Article

References (16)

1. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20: 1071-1092.
2. Hervey PS, Perry CM. Abacavir. A review of its clinical potential in patients with HIV infection. Drugs 2000; 60: 447-479.
3. Antinori A, Baldini F, Girardi E et al. Female sex and use of antiallergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15: 1579-1581.
4. Bersoff-Matcha SJ, Miller WC, Aberg JA et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-129.
5. Mahzude C, Jones S, Murad H et al. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16: 1566-1568.
6. Floridia M, Tomino C, Bucciardini R et al. A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection. AIDS Res Hum Retroviruses 2000; 16: 1809-1820.
7. Sabin CA, Fisher M, Churchill D et al. Long-term follow up of antiretroviral-naive HIV-positive patients treated with nevirapine. J AIDS 2001; 15: 462-465.
8. Knobel H, Miró JM, Domingo P et al. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial. J AIDS 2001; 28: 14-18.
9. Fumaz CR, Tuldrà A, Ferrer MJ et al. Quality of life, emotional status, and adherence of HIV-infected patients teated with efavirenz versus protease inhibitor-containing regimens. J AIDS 2002; 29: 244-253.
10. Currier JS, Spino C, Grimes J et al. Differences between women and men in adverse events and CD4 + responses to nucleoside analogue therapy for HIV infection. J AIDS 2000; 24: 316-324.
11. D'Arminio Monforte A, Cozzi Lepri A, Rezza G et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14: 499-507.
12. Bonfanti P, Ricci E, Landonio S et al. Predictors of protease-inhibitor-associated adverse events. Biomed Pharmacother 2001; 55: 321-323.
13. Wit FWNM, Weverling GJ, Weel J et al. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31.
14. Hennessy S, Strom BL, Berlin JA, Brennan PJ. Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infeceted individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. Gen Intern Med 1995; 10: 380-386.
15. Burger DM, Siebers MC, Hagen PWH et al. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J AIDS 2002; 29: 101-102.
16. Soriano V, Dona C, Barreiro P, Gonzalez-Lahoz J. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? AIDS 2000; 14: 1672-1673.